clinical trial · NCT03017547
A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome
Acute Respiratory Distress SyndromeIC14Placebo
brief summary
Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.
started
Jun 1, 2019
primary completion
Jun 1, 2020
completion
Jun 1, 2020
last updated
Aug 20, 2025
detailed description
Up to 160 patients with ARDS will be randomized to receive either IC14 at a dosage of 4 mg/kg on Study Day 1, then 2 mg/kg once daily on Study Days 2-4 or placebo for 4 days beginning within 48 hours of meeting inclusion criteria. Study participation will be for 28 days.
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Preliminary Efficacy Study of IC14 in Acute Respiratory Distress Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol